FDA Grants QT Imaging™ Clearance to Calculate Fibroglandular Volume of the Breast
NOVATO, Calif., Sept. 22, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted QT Imaging, Inc. 510(K) clearance to calculate the fibroglandular volume (FGV) of the breast and the ratio of FGV to total breast volume (TGV). This ratio can contribute to an assessment of risk for breast cancer and changes in this ratio can be used to measure the efficacy of medication used to treat or prevent breast cancer.